News

All news CSR Events General PERSONAL CARE Press release Products & Technologies Protéus

SEQENS announces the appointement of a new CEO

France-based SEQENS, a leader in the development and production of active pharmaceutical ingredients, pharmaceutical intermediates, and specialty ingredients, announces that Pascal Villemagne has been named Chief Executive Officer, effective 1st April 2025. Pascal brings a wealth of experience to the role, having previously served as CEO of CARBOGEN AMCIS, a company specializing in the manufacture … Continued

Read more

SEQENS new antiwear additive ROSCAN® 6253NV is registered on the LUSC list.

Pharma

Brenntag and SEQENS partner for the commercialization of non-GMP pharmaceutical intermediates in Europe

BBG Advanced Therapies and CELLforCURE partner to provide transatlantic manufacturing solutions for ATMPs

CELLforCURE by SEQENS to Manufacture Galapagos’ CAR T-Cell Therapy Candidates for Upcoming Trials

CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing

SEQENS and Novonesis announce strategic partnership for enhancing customer’s access to industrial biocatalytic processes

SEQENS and APPLEXION announce strategic partnership for the distribution of SEQENZYM FT

Smart Immune and CELLforCURE by SEQENS partner to industrialize SMART101 clinical batches manufacturing

Arkema Grants an Exclusive Technology License to SEQENS to manufacture PEKK

European Industry Summit: Pierre Luzeau, CEO of Seqens joins 73 industry leaders to call for a European Industrial Deal

Seqens and KK India petroleum specialties PVT LTD announce new partnership for lubricant additives in India

Seqens partners with Pleryon to develop and manufacture an innovative GMP Polymer to treat osteoarthritis

1 2